Rafee Talukder

Rafee Talukder

Auto-generated profile, based on publicly available information

Rafee Talukder

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
Dimitra Rafailia BakaloudiDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
RTRafee Talukder
Rafee Talukder
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
DMDimitrios Makrakis
Dimitrios Makrakis
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
PGPetros Grivas
Petros Grivas

13 November 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
DMDimitrios Makrakis
Dimitrios Makrakis
Dimitra Rafailia BakaloudiDimitra Rafailia Bakaloudi
Dimitra Rafailia Bakaloudi
RTRafee Talukder
Rafee Talukder
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
VKVadim S Koshkin
Vadim S Koshkin
To examine patient and disease characteristics, toxicity, and clinical outcomes for patients with advanced urothelial carcinoma (aUC) who are rechallenged with immune checkpoint inhibitor (ICI)-based therapy. In this retrospective cohort, we included patients treated with ICI for aUC after having prior ICI treatment. Endpoints included the evaluation of radiographic response and disease control rates with first and second ICI courses, outcomes based on whether there was a change in ICI class (anti-PD-1 vs. anti-PD-L1), and assessment of the reasons for ICI discontinuation. We identified 25 patients with aUC from 9 institutions who received 2 separate ICI courses. ORR with first ICI and second ICI were 39% and 13%, respectively. Most patients discontinued first ICI due to progression (n = 19) or treatment-related toxicity (n = 4). Thirteen patients received non-ICI treatment between the first and second ICI, and 12 patients changed ICI class (anti-PD-1 vs. anti-PD-L1) at rechallenge. Among 10 patients who changed ICI class, 8 (80%) had progressive disease as best response with second ICI, while among 12 patients re-treated with the same ICI class, only 3 (25%) had progressive disease as best response at the time of rechallenge. With second ICI, most patients discontinued treatment due to progression (n = 18) or patient preference (n = 2). A proportion of patients with aUC rechallenged with ICI-based regimens may achieve disease control, supporting clinical trials in that setting, especially with ICI-based combinations. Future studies are needed to validate our results and should also focus on identifying biomarkers predictive of benefit with ICI rechallenge.

1 October 2025 in Cancer Medicine
Verified
Journal Article
Open access
ANAmanda Nizam
Amanda Nizam
CNCharles B. Nguyen
Charles B. Nguyen
JLJinju Li
Jinju Li
EZEmily C. Zabor
Emily C. Zabor
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
VKVadim S Koshkin
Vadim S Koshkin
Introduction: Enfortumab vedotin‐ejfv (EV), an antibody–drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real‐world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV‐related dermatologic toxicities, but survival implications remain unclear. This analysis assessed the safety of EV monotherapy and the impact of dermatologic and neurologic toxicities on efficacy outcomes in a multi‐institutional cohort. Materials and Methods: UNITE is a multicenter, retrospective study across 16 US sites of patients with aUC treated with targeted agents, including EV. Primary endpoints were the incidence of EV treatment‐related adverse events (TRAEs, any grade) and TRAE‐related treatment modifications. Secondary endpoints included a comparison of ORR, progression‐free survival (PFS), and overall survival (OS) between patients with and without dermatologic toxicities and neuropathy. To reduce immortal time bias, Cox regression models incorporated TRAEs as time‐dependent covariates to adjust for EV treatment duration as well as Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, and liver metastases. Results: Between 2018 and 2023, 485 patients with aUC received > 1 dose of EV monotherapy. Most (67%) received > 2 prior therapy lines. Any grade TRAEs occurred in 77%, most frequently neuropathy (36%) and dermatologic toxicities (27%); 57% required treatment modification and 21% discontinued EV, primarily due to neuropathy (9%) and fatigue (3%). Patients with dermatologic toxicities and neuropathy had higher ORR (56% vs. 42%; p = 0.007 and 64% vs. 35%; p < 0.0001, respectively). Neuropathy was independently associated with improved OS (HR 0.66; 95% CI 0.50–0.87; p = 0.002); dermatologic TRAEs were not associated with PFS or OS benefit. Conclusions: EV safety outside clinical trials was consistent with prior reports, with no new signals. Treatment modifications were most often due to neuropathy, dermatologic toxicities, and fatigue. Both dermatologic toxicities and neuropathy correlated with higher ORR, but only neuropathy was independently associated with improved OS.

19 August 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
RTRafee Talukder
Rafee Talukder
DMDimitrios Makrakis
Dimitrios Makrakis
GLGenevieve Ihsiu Lin
Genevieve Ihsiu Lin
LDLeonidas N. Diamantopoulos
Leonidas N. Diamantopoulos
SDScott Dawsey
Scott Dawsey
AKAli Raza Khaki
Ali Raza Khaki